Prevalence of the Metabolic Syndrome in Psoriasis: Results from the National Health and Nutrition Examination Survey, 2003-2006

Overview

Journal Arch Dermatol

Specialty Dermatology

Date 2010 Dec 22

PMID 21173301

Citations 86

Authors

Thorvardur Jon Love

Abrar A Qureshi

Elizabeth Wood Karlson

Joel M Gelfand

Hyon K Choi

Affiliations

Soon will be listed here.

Abstract

Objectives: To estimate the prevalence of the metabolic syndrome among individuals with psoriasis and to examine the association between these 2 conditions in the general US population.

Design: Cross-sectional health survey of a nationally representative random sample of the noninstitutionalized civilian US population.

Setting: The National Health and Nutrition Examination Survey, 2003-2006.

Participants: The study included 6549 participants aged 20 to 59 years.

Main Outcome Measures: Prevalence of the metabolic syndrome defined by the revised National Cholesterol Education Program Adult Treatment Panel III definition and odds ratios for associations after adjustment for age, sex, race/ethnicity, smoking status, and C-reactive protein levels.

Results: The prevalence of the metabolic syndrome was 40% among psoriasis cases and 23% among controls. According to 2008 US census data, the projected number of patients with psoriasis aged 20 to 59 years with the metabolic syndrome was 2.7 million. The univariate and multivariate odds ratios for patients with psoriasis and the metabolic syndrome were 2.16 (95% confidence interval, 1.16 to 4.03) and 1.96 (1.01 to 3.77), respectively. The most common feature of the metabolic syndrome among patients with psoriasis was abdominal obesity, followed by hypertriglyceridemia and low levels of high-density lipoprotein cholesterol.

Conclusions: The prevalence of the metabolic syndrome is high among individuals with psoriasis. Given the serious complications associated with the metabolic syndrome, this frequent comorbidity should be recognized and taken into account in the long-term treatment of individuals with psoriasis.

Citing Articles

Clinical Implications of Metabolic Syndrome in Psoriasis Management.

Mustata M, Neagoe C, Ionescu M, Predoi M, Mitran A, Ianosi S Diagnostics (Basel). 2024; 14(16).

PMID: 39202262 PMC: 11353756. DOI: 10.3390/diagnostics14161774.

Diabetes and obesity burden and improvements in cardiometabolic parameters in patients with psoriasis or psoriatic arthritis receiving apremilast in a real-world setting.

Cavanaugh C, Orroth K, Qian X, Kumparatana P, Klyachkin Y, Colgan S JAAD Int. 2024; 16:244-251.

PMID: 39072263 PMC: 11279948. DOI: 10.1016/j.jdin.2024.02.016.

Increased serum ATG5 as a marker of autophagy in psoriasis vulgaris patients: a cross-sectional study.

Abu El-Hamd M, Abdel-Hamid S, Hamdy A, Abdelhamed A Arch Dermatol Res. 2024; 316(8):491.

PMID: 39066827 DOI: 10.1007/s00403-024-03219-2.

A Bibliometric Analysis of Global Research Trends in Psoriasis and Metabolic Syndrome.

Tang Z, Yang J, Yu C, Dong M, Wang R, Li C Clin Cosmet Investig Dermatol. 2024; 17:365-382.

PMID: 38352064 PMC: 10863501. DOI: 10.2147/CCID.S446966.

Spatial transcriptomics stratifies psoriatic disease severity by emergent cellular ecosystems.

Castillo R, Sidhu I, Dolgalev I, Chu T, Prystupa A, Subudhi I Sci Immunol. 2023; 8(84):eabq7991.

PMID: 37267384 PMC: 10502701. DOI: 10.1126/sciimmunol.abq7991.

References

Gelfand J, Stern R, Nijsten T, Feldman S, Thomas J, Kist J . The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol. 2005; 52(1):23-6. DOI: 10.1016/j.jaad.2004.07.045. View

Ford E . Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence. Diabetes Care. 2005; 28(7):1769-78. DOI: 10.2337/diacare.28.7.1769. View

Dreiher J, Weitzman D, Davidovici B, Shapiro J, Cohen A . Psoriasis and dyslipidaemia: a population-based study. Acta Derm Venereol. 2008; 88(6):561-5. DOI: 10.2340/00015555-0510. View

Mehta N, Azfar R, Shin D, Neimann A, Troxel A, Gelfand J . Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database. Eur Heart J. 2009; 31(8):1000-6. PMC: 2894736. DOI: 10.1093/eurheartj/ehp567. View

Gelfand J, Troxel A, Lewis J, Kurd S, Shin D, Wang X . The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007; 143(12):1493-9. DOI: 10.1001/archderm.143.12.1493. View

Schon M, Boehncke W . Psoriasis. N Engl J Med. 2005; 352(18):1899-912. DOI: 10.1056/NEJMra041320. View

Gelfand J, Neimann A, Shin D, Wang X, Margolis D, Troxel A . Risk of myocardial infarction in patients with psoriasis. JAMA. 2006; 296(14):1735-41. DOI: 10.1001/jama.296.14.1735. View

Facchini F, Hollenbeck C, Jeppesen J, Chen Y, Reaven G . Insulin resistance and cigarette smoking. Lancet. 1992; 339(8802):1128-30. DOI: 10.1016/0140-6736(92)90730-q. View

Kurd S, Gelfand J . The prevalence of previously diagnosed and undiagnosed psoriasis in US adults: results from NHANES 2003-2004. J Am Acad Dermatol. 2008; 60(2):218-24. PMC: 4762027. DOI: 10.1016/j.jaad.2008.09.022. View

10.

Manson J, Ajani U, Liu S, Nathan D, Hennekens C . A prospective study of cigarette smoking and the incidence of diabetes mellitus among US male physicians. Am J Med. 2000; 109(7):538-42. DOI: 10.1016/s0002-9343(00)00568-4. View

11.

Martinez-Abundis E, Reynoso-von Drateln C, Hernandez-Salazar E, Gonzalez-Ortiz M . Effect of etanercept on insulin secretion and insulin sensitivity in a randomized trial with psoriatic patients at risk for developing type 2 diabetes mellitus. Arch Dermatol Res. 2007; 299(9):461-5. DOI: 10.1007/s00403-007-0784-3. View

12.

Brandrup F, Green A . The prevalence of psoriasis in Denmark. Acta Derm Venereol. 1981; 61(4):344-6. View

13.

Tobin A, Veale D, FitzGerald O, Rogers S, Collins P, OShea D . Cardiovascular disease and risk factors in patients with psoriasis and psoriatic arthritis. J Rheumatol. 2010; 37(7):1386-94. DOI: 10.3899/jrheum.090822. View

14.

Sommer D, Jenisch S, Suchan M, Christophers E, Weichenthal M . Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res. 2006; 298(7):321-8. DOI: 10.1007/s00403-006-0703-z. View

15.

. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002; 106(25):3143-421. View

16.

Higa-Sansone G, Szomstein S, Soto F, Brasecsco O, Cohen C, Rosenthal R . Psoriasis remission after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Obes Surg. 2004; 14(8):1132-4. DOI: 10.1381/0960892041975569. View

17.

Saraceno R, Schipani C, Mazzotta A, Esposito M, Di Renzo L, De Lorenzo A . Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis. Pharmacol Res. 2008; 57(4):290-5. DOI: 10.1016/j.phrs.2008.02.006. View

18.

Gisondi P, Tessari G, Conti A, Piaserico S, Schianchi S, Peserico A . Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol. 2007; 157(1):68-73. DOI: 10.1111/j.1365-2133.2007.07986.x. View

19.

Qureshi A, Choi H, Setty A, Curhan G . Psoriasis and the risk of diabetes and hypertension: a prospective study of US female nurses. Arch Dermatol. 2009; 145(4):379-82. PMC: 2849106. DOI: 10.1001/archdermatol.2009.48. View

20.

Gisondi P, Cotena C, Tessari G, Girolomoni G . Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study. J Eur Acad Dermatol Venereol. 2007; 22(3):341-4. DOI: 10.1111/j.1468-3083.2007.02429.x. View